Development of a Protocol for Obtaining a Homologous Cell Product of Animal Origin Intended for Preclinical Studies of Antitumor Vaccine CaTeVac.
biomedical cell product
dendritic cells
experimental oncology
preclinical studies
relevant models
Journal
Bulletin of experimental biology and medicine
ISSN: 1573-8221
Titre abrégé: Bull Exp Biol Med
Pays: United States
ID NLM: 0372557
Informations de publication
Date de publication:
22 Jun 2024
22 Jun 2024
Historique:
received:
01
11
2023
medline:
22
6
2024
pubmed:
22
6
2024
entrez:
21
6
2024
Statut:
aheadofprint
Résumé
When developing a program of preclinical studies of human cell-based drugs intended for adoptive immunotherapy of cancer patients, the biological effect should be substantiated by data describing their immunological action. Administration and study of human autologous dendritic cell vaccine to immunocompetent animals are not adequate in terms of immunological compatibility. It is possible to use immunocompromised, knockout, or transgenic animals or to obtain a homologous cellular product, namely, a preparation based on animal cells using a technology similar to obtaining the original preparation for clinical practice in humans. Within the framework of this study, we have developed a protocol for obtaining a homologous cell product based on animal dendritic cells (mice, rats) according to a similar technology for obtaining human vaccine dendritic cells, and demonstrated the comparability of morphological characteristics and expression of differentiation antigens of dendritic cells (CD11c, CD80, CD86, and CD83) of animals (mice) and humans.
Identifiants
pubmed: 38907062
doi: 10.1007/s10517-024-06113-z
pii: 10.1007/s10517-024-06113-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Jeng LB, Liao LY, Shih FY, Teng CF. Dendritic-cell-vaccine-based immunotherapy for hepatocellular carcinoma: clinical trials and recent preclinical studies. Cancers (Basel). 2022;14(18):4380. doi: https://doi.org/10.3390/cancers14184380
doi: 10.3390/cancers14184380
pubmed: 36139542
pmcid: 9497058
Novik AV, Nekhaeva TL, Semenova AI, Danilova AB, Latipova DKh, Pipia NP, Teletaeva GM, Avdonkina NA, Zozulya AYu, Blokhina ML, Oganesyan AP, Protsenko SA, Baldueva IA. Ten-year experience of pharmacotherapy for soft tissue sarcomas. Farmateka. 2020;27(11):30-35. Russian. https://doi.org/10.18565/pharmateca.2020.11.30-34
Wang Y, Xiang Y, Xin VW, Wang XW, Peng XC, Liu XQ, Wang D, Li N, Cheng JT, Lyv YN, Cui SZ, Ma Z, Zhang Q, Xin HW. Dendritic cell biology and its role in tumor immunotherapy. J. Hematol. Oncol. 2020;13(1):107. doi: https://doi.org/10.1186/s13045-020-00939-6
doi: 10.1186/s13045-020-00939-6
pubmed: 32746880
pmcid: 7397618
Order No. 512n of August 8, 2018 «On approval of the rules of good practice for working with biomedical cell products ». Electronic fund of legal, regulatory and technical documents: information and reference website. Codex information company 2023. URL: https://docs.cntd.ru/document/542630852
Guidelines for Biomedical Evaluation of Biomedical Cellular Products. Merkulov VA, ed. Moscow, 2023. Russian.
Yu J, Sun H, Cao W, Song Y, Jiang Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp. Hematol. Oncol. 2022;11(1):3. doi: https://doi.org/10.1186/s40164-022-00257-2
doi: 10.1186/s40164-022-00257-2
pubmed: 35074008
pmcid: 8784280
Melnikova EV, Merkulova OV, Chaplenko AA, Merkulov VA. Design of preclinical studies of biomedical cell products: characteristics, key principles and requirements. Bioprepar. Profilakt. Diagnost. Lechenie. 2017;17(3):133-144. Russian.
Tikhomirova AV, Goryachev DV, Merkulov VA, Lysikova IV, Gubenko AI, Zebrev AI, Solovieva AP, Romodanovsky DP, Melnikova EV. Preclinical and clinical aspects of the development of biomedical cell products. Vedom. Nauch. Tsentra Eksper. Sredstv Med. Primenen. 2018;8(1):23-35. Russian. https://doi.org/10.30895/1991-2919-2018-8-1-23-35
FDA. Preclinical Assessment of Investigational Cellular and Gene Therapy Products. Docket Number: FDA-2012-D-1038. November 2013. URL: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preclinical-assessment-investigational-cellular-and-gene-therapy-products
Nehaeva TL. Autologous dendritic cell vaccine optimization for therapy of patients with disseminated malignant neoplasms. Sib. Onkol. Zh. 2013;(3):52-56. Russian.
Baldueva IA, Danilova AB, Nekhaeva TL, Avdonkina NA, Emelyanova NV, Belyaev AM. Patent RU No. 2714208. Cell product for loading and activation of human dendrite cells. Bull. No. 5. Published February 13, 2020.